Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Nateglinide

Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.

DRUG

Acarbose

Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.

Trial Locations (3)

200065

Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai

200233

Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai

310016

Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY